120 related articles for article (PubMed ID: 30171788)
1. Small Heat Shock Proteins B1 and B6: Which One is the Most Effective Adjuvant in Therapeutic HPV Vaccine?
Bolhassani A; Shahbazi S; Milani A; Nadji SA
IUBMB Life; 2018 Oct; 70(10):1002-1011. PubMed ID: 30171788
[TBL] [Abstract][Full Text] [Related]
2. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
Shahbazi S; Bolhassani A
Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
[TBL] [Abstract][Full Text] [Related]
3. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
4. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
[TBL] [Abstract][Full Text] [Related]
5. Modified DCs and MSCs with HPV E7 antigen and small Hsps: Which one is the most potent strategy for eradication of tumors?
Bolhassani A; Shahbazi S; Agi E; Haghighipour N; Hadi A; Asgari F
Mol Immunol; 2019 Apr; 108():102-110. PubMed ID: 30802787
[TBL] [Abstract][Full Text] [Related]
6. [Heat-shock protein enhances immunogenicity of E7 oncoprotein of human papillomavirus included in chimeric construction (E7 HPV-HSP70)].
Sveshnikov PG; Solopova ON; Kurbatova EA; Shevchik IuS; Baranovskiĭ PM; Ul'ianov AM; Bokov MN; Kiselev VI
Zh Mikrobiol Epidemiol Immunobiol; 2010; (3):36-9. PubMed ID: 20734716
[TBL] [Abstract][Full Text] [Related]
7. Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women.
Ramezani A; Aghakhani A; Soleymani S; Bavand A; Bolhassani A
BMC Infect Dis; 2019 Feb; 19(1):142. PubMed ID: 30755156
[TBL] [Abstract][Full Text] [Related]
8. Development of novel HPV therapeutic vaccine constructs based on engineered exosomes and tumor cell lysates.
Rezaei F; Bolhassani A; Sadat SM; Arashkia A; Fotouhi F; Milani A; Pordanjani PM
Life Sci; 2024 Mar; 340():122456. PubMed ID: 38266814
[TBL] [Abstract][Full Text] [Related]
9. Protein vaccination with HPV16 E7/Pep-1 nanoparticles elicits a protective T-helper cell-mediated immune response.
Mardani G; Bolhassani A; Agi E; Shahbazi S; Mehdi Sadat S
IUBMB Life; 2016 Jun; 68(6):459-67. PubMed ID: 27094221
[TBL] [Abstract][Full Text] [Related]
10. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
13. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
14. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
[TBL] [Abstract][Full Text] [Related]
15. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.
Ohlschläger P; Quetting M; Alvarez G; Dürst M; Gissmann L; Kaufmann AM
Int J Cancer; 2009 Jul; 125(1):189-98. PubMed ID: 19358269
[TBL] [Abstract][Full Text] [Related]
17. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
[TBL] [Abstract][Full Text] [Related]
19. Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model.
Kadkhodayan S; Jafarzade BS; Sadat SM; Motevalli F; Agi E; Bolhassani A
Immunol Lett; 2017 Aug; 188():38-45. PubMed ID: 28602843
[TBL] [Abstract][Full Text] [Related]
20. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]